

Dutch Liver Retreat 2022 Online

FXR / Bile acids

- 09.00-09.20 Role of bile acid signalling via FXR in the development and function of brown adipose tissue
- 09.20-09.40 Identification of pruriceptor activating bile and plasma compounds in cholestatic itch
- 09.40-10.00 Serum autoantibodies against annexin A11 may weaken the biliary bicarbonate umbrella in IgG4-related cholangitis
- 10.00-10.20 A screening approach to identify novel therapeutic targets for immune-mediated cholestatic liver diseases
- 10.20-10.40 Short break

NAFLD/NASH

- 10.40-11.00 MicroRNA-26b protects against NASH development by ameliorating hepatic lipid levels, inflammation and fibrosis in mice
- 11.00-11.20 Pneumococcal immunization against oxLDL decreases tumor burden in NASH-derived hepatocellular carcinoma
- 11.20-11.40 Low production of 12 α -hydroxylated bile acids prevents hepatic steatosis in Cyp2c70-knockout mice by reducing fat absorption
- 11.40-12.00 An advanced human liver in vitro 3D model to test the effects of selective FXR isoform expression and activation in NASH
- 12.00-12.40 Lunch break

New Models

- 12.40-13.00 Induction of branching morphogenesis in cholangiocarcinoma organoids in vitro improves similarity with the original tumor
- 13.00-13.20 Cancer-associated fibroblasts nurture LGR5 marked liver tumor-initiating cells and promote their metastasis
- 13.20-13.40 Modelling hepatic Glycogen Storage Disease type 1 using Precision-Cut Liver Slices – opportunities, challenges and open questions
- 13.40-14.00 Dissecting the role of non-malignant cells in the hepatocellular carcinoma tumor-microenvironment at a single cell level; the establishment of single cell phenomics
- 14.00-14.20 Short break

HCC/Fibrosis

- 14.20-14.40 Hepatocytic loss of the endosomal sorting complex Retromer in adult mice leads to ductular reaction and primary cholangiopathy
- 14.40-15.00 Role of soluble adenylyl cyclase in the formation and growth of liver tumors
- 15.00-15.20 Multi-omics analysis of human livers reveals intrahepatic inflammation variation across chronic hepatitis B infection phases
- 15.20-15.40 Liver Cirrhosis Etiology Impacts the Circulating Immune mediators of Early Stage Hepatocellular Carcinoma
- 15.40-16.00 Short break

Keynote

- 16.00-16.45 Bart Staels: Pathways in the Transition from Fatty Liver to NASH?
- 16.45-17.15 Best presentation and saying goodbye